Our Technology

Our advanced platform enables real-time profiling of Circulating Tumor Cells (CTCs), which are critical indicators of cancer progression and treatment efficacy. This platform relies exclusively on autofluorescence technology, combined with cutting-edge microfluidics and optoelectronic systems, to provide highly sensitive and specific detection of CTCs without the need for labeling.

Our microfluidic device incorporates both active and passive sorting mechanisms, ensuring efficient and precise isolation of CTCs from blood samples. This dual approach minimizes common issues like clogging and enhances sorting accuracy.

By leveraging the natural autofluorescence signatures of CTCs, our technology differentiates these cells from other cell types with exceptional precision. This allows for targeted treatment selection based on the unique characteristics of the CTCs.

The integration of advanced signal processing and machine learning algorithms significantly enhances the detection and enumeration of CTCs. This ensures that clinicians receive accurate and reliable data to inform their treatment decisions.

Our platform features a robust AI-driven system that continuously monitors and analyzes the data collected from CTC profiling. This system provides real-time updates on CTC characteristics, enabling clinicians to make timely adjustments to treatment plans.